Weight loss: EnteroMedics names new operating chief ahead of FDA bid

February 20, 2013 by MassDevice staff

Weight-loss neurostimulation systems maker EnteroMedics gives CFO Greg Lea an additional role as COO as the company prepares to make its FDA bid.

EnteroMedics logo

Minnesota weight-loss devices maker EnteroMedics (NSDQ:ETRM) announced today that CFO and senior vice president Greg Lea had also been appointed chief operating officer.

Lea will help the company get through its 2013 objective to make progress on its pre-market approval application for the Maestro vagal blocking system, an implanted neurostimulator designed to stimulate the Vagus nerve in order to alter a patient's eating habits by modifying physiological cravings.

Sign up to get our free newsletters delivered right to your inbox.

"Greg has been a member of EnteroMedics' strategic management team since joining the company over 5 years ago," president & CEO Mark Knudson said in prepared remarks. "With our attention now fully on the U.S. regulatory process and its associated activities, his leadership and depth of knowledge provide a strong basis for successful management of the critical period the company's operations are now entering."

The company may have some hurdles ahead in convincing FDA regulators to put the stamp of approval on the Maestro system. The device failed to meet pre-defined endpoints in its recent ReCharge pivotal trial, EnteroMedics announced earlier this month.